Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis

SummaryImpaired histone acetylation was recognized to be involved in carcinogenesis. Furthermore, histone deacetylase (HDAC) inhibitors induce differentiation of breast cancer cells and inhibit tumour growth. These results prompted us to study HDAC-1 and -3 expression in breast tumours to establish their potential therapeutic and prognostic significance.HDAC-1 und HDAC-3 protein expression was analyzed immunohistochemically on a tissue microarray (TMA) containing 600 core biopsies from 200 patients. HDAC-1 and -3 expression was correlated to steroid hormone receptor-, Her2/neu- and proliferation status of tumours as well as to overall and disease free survival.Moderate or strong nuclear immunoreactivity for HDAC-1 was observed in 39.8% and for HDAC-3 in 43.9% of breast carcinomas. HDAC-1 and -3 expression correlated significantly with oestrogen and progesterone receptor expression (both p< 0.001). HDAC-1 expression predicted significantly better disease free survival (DFS: p=0.044), in particular, in patients with small tumours of all differentiation types (DFS: p=0.016). Multivariate analysis demonstrated that HDAC-1 is an independent prognostic marker.Our data suggest that evaluation of HDAC-1 protein expression enables a more precise assessment of the prognosis of breast cancer patients. Thus, HDAC-1 expression analysis might be clinically useful to facilitate an individual, risk-directed, adjuvant systemic therapy in breast cancer patients.

[1]  K. Glaser,et al.  Role of class I and class II histone deacetylases in carcinoma cells using siRNA. , 2003, Biochemical and biophysical research communications.

[2]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[3]  R C Coombes,et al.  Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  N. Davidson,et al.  Role of DNA Methylation and Histone Acetylation in Steroid Receptor Expression in Breast Cancer , 2001, Journal of Mammary Gland Biology and Neoplasia.

[5]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[6]  Y. Chiew,et al.  Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Kuang-Hung Cheng,et al.  Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code , 2003, Annals of the New York Academy of Sciences.

[8]  G. Kouraklis,et al.  Histone deacetylase inhibitors and anticancer therapy. , 2002, Current medicinal chemistry. Anti-cancer agents.

[9]  Christin Müller,et al.  Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis , 2003, Journal of Cancer Research and Clinical Oncology.

[10]  M. Guenther,et al.  The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3 , 2001, Molecular and Cellular Biology.

[11]  R. Gelber,et al.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Julia Tischler,et al.  The Tumor Suppressor p53 and Histone Deacetylase 1 Are Antagonistic Regulators of the Cyclin-Dependent Kinase Inhibitor p21/WAF1/CIP1 Gene , 2003, Molecular and Cellular Biology.

[13]  P. Atadja,et al.  Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. , 2003, Molecular cancer therapeutics.

[14]  R. Gelber,et al.  Meeting highlights: international consensus panel on the treatment of primary breast cancer. , 2002, Journal of the National Cancer Institute.

[15]  D. Dean,et al.  Rb-mediated chromatin structure regulation and transcriptional repression , 2001, Oncogene.

[16]  C. Cordon-Cardo,et al.  Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. , 2001, The American journal of pathology.

[17]  W. D. Cress,et al.  Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.

[18]  S. Pileri,et al.  DIFFERENTIATION PATHWAYS IN PRIMARY INVASIVE BREAST CARCINOMA AS SUGGESTED BY INTERMEDIATE FILAMENT AND BIOPATHOLOGICAL MARKER EXPRESSION , 1996, The Journal of pathology.

[19]  H. Kawai,et al.  Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α , 2003, International journal of cancer.

[20]  Dipali Sharma,et al.  A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine , 2003, Breast Cancer Research and Treatment.

[21]  M. Schemper,et al.  Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. , 1990, Cancer research.

[22]  R. Yarden,et al.  BRCA1 interacts with components of the histone deacetylase complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. O’Carroll,et al.  Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression , 2002, The EMBO journal.

[24]  Z. Hall.  Cancer , 1906, The Hospital.

[25]  S. Naber,et al.  Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. , 2000, Cancer research.

[26]  R. Clarke,et al.  Steroid receptors and proliferation in the human breast , 2003, Steroids.

[27]  C. Poremba,et al.  Telomerase activity in human proliferative breast lesions. , 1998, International journal of oncology.

[28]  Eun Ryoung Jang,et al.  The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen , 2004, Oncogene.

[29]  司履生.  Cancer epigenetics , 2006 .